Relay Therapeutics Inc
NASDAQ:RLAY
Net Margin
Relay Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
US |
Relay Therapeutics Inc
NASDAQ:RLAY
|
729.1m USD |
-1 698%
|
||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
||
US |
Abbvie Inc
NYSE:ABBV
|
308.6B USD |
9%
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
142.6B USD |
13%
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
113B USD |
0%
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.7B USD |
-5%
|
||
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD |
18%
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.7B USD |
34%
|
||
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
argenx SE
XBRU:ARGX
|
38.8B EUR |
-5%
|
Relay Therapeutics Inc
Glance View
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 245 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Relay Therapeutics Inc's most recent financial statements, the company has Net Margin of -1 698%.